



# Lymphatic System Metastasis

Edited by  
Leonard Weiss  
Harvey A. Gilbert  
Samuel C. Ballon

# Lymphatic System Metastasis

EDITED BY

Leonard Weiss, Sc.D., M.D., Ph.D.

*Department of Experimental Pathology  
Roswell Park Memorial Institute  
Buffalo, New York*

Harvey A. Gilbert, M.D.

*Department of Radiation Therapy  
Southern California Permanente Medical Group  
Los Angeles, California*

Samuel C. Ballon, M.D.

*Section of Gynecologic Oncology  
Stanford University Medical Center  
Stanford University School of Medicine  
Stanford, California*



G. K. Hall Medical Publishers  
Boston, Massachusetts

The authors and publisher have worked to ensure that all information in this book concerning drug dosages, schedules, and routes of administration is accurate at the time of publication. As medical research and practice advance, however, therapeutic standards may change. For this reason, and because human and mechanical errors will sometimes occur, we recommend that our readers consult the *PDR* or a manufacturer's product information sheet prior to prescribing or administering any drug discussed in this volume.

Copyright © 1980 by G. K. Hall & Co.

G. K. Hall Medical Publishers  
70 Lincoln Street  
Boston, Massachusetts 02111

All rights, including that of translation into other languages, reserved. Photomechanical reproduction (photocopy, microcopy) of this book or parts thereof without special permission of the publisher is prohibited.

80 81 82 83/4 3 2 1

Lymphatic system metastasis.

"Expanded versions of papers given at a small workshop on metastasis in the lymphatic system, held on May 31st and June 1st, 1979, at the University of California at Los Angeles Faculty Center."

Includes bibliographies and index.

1. Lymphatic metastasis—Congresses. I. Weiss, Leonard. II. Gilbert, Harvey A., 1940- III. Ballon, Samuel C. [DNLM: 1. Lymphatic metastasis—Congresses. WH700 L985 1979]

RC280.L9L92

616.9'94'42

79-24913

ISBN 0-8161-2142-7

# Lymphatic System Metastasis

Metastasis:  
A Monograph Series

- Volume One  
*Pulmonary Metastasis* 1978
- Volume Two  
*Brain Metastasis* 1980
- Volume Three  
*Lymphatic System Metastasis* 1980
- Volume Four  
*Bone Metastasis* (in preparation)
- Volume Five  
*Liver Metastasis* (in preparation)

# Contributors

**Samuel C. Ballon, M.D.**

Section of Gynecologic Oncology  
Stanford University  
Medical Center  
Stanford University  
School of Medicine  
Stanford, California 94305

**Michael L. Berman, M.D.**

Division of Gynecologic  
Oncology  
University of Pittsburgh  
Medical School  
Magee Women's Hospital  
Pittsburgh, Pennsylvania 15213

**David Berry, M.D.**

Department of Urology  
Tulane University Medical Center  
1415 Tulane Avenue  
New Orleans, Louisiana 70112

**William Brand, M.D.**

Radiation Therapy Center  
Northwestern Memorial Hospital  
250 East Superior  
Chicago, Illinois 60611

**John E. Byfield, M.D., Ph.D.**

Division of Radiation Oncology  
University of California  
School of Medicine  
San Diego, California 92110

**Ian Carr, M.D., Ph.D.**

Department of Pathology  
University of Saskatchewan  
Saskatoon, Saskatchewan  
Canada S7N 0W0

**Jean Carr, M.D.**

Department of Physiology  
University of Saskatchewan  
Saskatoon, Saskatchewan  
Canada S7N 0W0

**Thomas W. Castaldo, M.D.**

Division of Gynecologic  
Oncology  
North Shore University Hospital  
Manhasset, New York 11030

**Ronald A. Castellino, M.D.**

Department of Radiology  
Stanford University  
Medical Center  
Stanford University  
School of Medicine  
Stanford, California 94305

**Terry Chamorro, R.N.**

Division of Gynecologic  
Oncology  
University of California  
School of Medicine  
Los Angeles, California 90024

**Paul Y. M. Chan, M.D.**

Department of Radiation Therapy  
Southern California  
Permanente Medical Group  
1510 North Edgemont Street  
Los Angeles, California 90027

**Isidore Cohn, Jr., M.D.**

Department of Surgery  
Louisiana State University  
School of Medicine  
1542 Tulane Avenue  
New Orleans, Louisiana 70112

**James D. Collins, M.D.**  
Department of Radiology  
University of California  
School of Medicine  
Los Angeles, California 90024

**Jean B. deKernion, M.D.**  
Department of Urology  
Tulane University Medical Center  
1415 Tulane Avenue  
New Orleans, Louisiana 70112

**Frederick R. Eilber, M.D.**  
Department of Surgery,  
Division of Oncology  
University of California  
School of Medicine  
Los Angeles, California 90024

**Isaiah J. Fidler, D.V.M., Ph.D.**  
Cancer Metastasis and  
Treatment Laboratory  
Frederick Cancer Research Center  
Post Office Box B  
Frederick, Maryland 21701

**Harvey A. Gilbert, M.D.**  
Department of Radiation Therapy  
Southern California  
Permanente Medical Group  
1510 North Edgemont Street  
Los Angeles, California 90027

**Dorothy Graves, Ph.D.**  
Department of  
Experimental Pathology  
Roswell Park Memorial Institute  
Buffalo, New York 14263

**James E. Goodnight, Jr.,  
M.D., Ph.D.**  
Division of Oncology  
Department of Surgery  
University of California  
School of Medicine  
Los Angeles, California 90024

**Barry Green, M.D.**  
Radiology Department  
University of Texas System  
Cancer Center  
M. D. Anderson Hospital and  
Tumor Institute  
6723 Bertner Drive  
Houston, Texas 77030

**Kay E. Hermes, B.S.**  
Section of Thoracic Surgery  
University of Texas System  
Cancer Center  
M. D. Anderson Hospital and  
Tumor Institute  
6723 Bertner Drive  
Houston, Texas 77030

**Frederic P. Herter, M.D.**  
Columbia Presbyterian Hospital  
College of Physicians and  
Surgeons  
622 West 168th Street  
New York, New York 10032

**Brace L. Hintz, M.D.**  
Department of Radiation  
Therapy  
Southern California  
Permanente Medical Group  
1510 North Edgemont Street  
Los Angeles, California 90027

**Herbert C. Hoover, Jr., M.D.**  
Department of Surgery  
Johns Hopkins School  
of Medicine  
Baltimore, Maryland 21218

**David H. Hussey, M.D.**  
Department of Radiation Therapy  
University of Texas System  
Cancer Center  
M. D. Anderson Hospital and  
Tumor Institute  
6723 Bertner Drive  
Houston, Texas 77030

**Norman Jaffe,**  
**MB.B.Ch., Dip. Paed.**  
 Pediatric Department  
 University of Texas System  
 Cancer Center  
 M. D. Anderson Hospital and  
 Tumor Institute  
 6723 Bertner Drive  
 Houston, Texas 77030

**A. Robert Kagan, M.D.**  
 Department of Radiation Therapy  
 Southern California  
 Permanente Medical Group  
 1510 North Edgemont Street  
 Los Angeles, California 90027

**Leo D. Lagasse, M.D.**  
 Division of Gynecologic  
 Oncology  
 University of California  
 School of Medicine  
 Los Angeles, California 90024

**Yeu-Tsu N. Margaret Lee, M.D.**  
 Department of Surgery  
 University of Southern California  
 School of Medicine and  
 Tumor Surgery Service  
 Los Angeles County-USC  
 Medical Center  
 Los Angeles, California 90033

**Malcolm S. Mitchell, M.D.**  
 University of Southern California  
 Comprehensive Cancer Center  
 1200 North State Street  
 Los Angeles, California 90033

**Clifton F. Mountain, M.D.**  
 Section of Thoracic Surgery  
 University of Texas System  
 Cancer Center  
 M. D. Anderson Hospital and  
 Tumor Institute  
 6723 Bertner Drive  
 Houston, Texas 77030

**Herman Nussbaum, M.D.**  
 Department of Radiation Therapy  
 Southern California  
 Permanente Medical Group  
 1510 North Edgemont Street  
 Los Angeles, California 90027

**Carlos A. Perez, M.D.**  
 Division of Radiation Oncology  
 Mallinckrodt Institute of Radiology  
 Washington University  
 School of Medicine  
 4511 Forest Park Boulevard  
 St. Louis, Missouri 63108

**Edmund S. Petrilli, M.D.**  
 Division of Gynecologic  
 Oncology  
 Georgetown University and  
 Affiliated Hospital  
 Washington, D.C. 20007

**David Plotkin, M.D.**  
 Brotman Memorial Hospital  
 3800 Hughes Avenue  
 Culver City, California 90230

**Aroor R. Rao, M.D.**  
 Department of Radiation Therapy  
 Southern California  
 Permanente Medical Group  
 1510 North Edgemont Street  
 Los Angeles, California 90027

**Sally Shaw, M.D.**  
 Department of Radiology  
 City of Hope National  
 Medical Center  
 Duarte, California 91010

**Charles A. Slanetz, M.D.**  
 Columbia Presbyterian Hospital  
 College of Physicians and  
 Surgeons  
 622 West 168th Street  
 New York, New York 10032



**Carleton C. Stewart, M.D.**  
Division of Radiation Oncology  
Mallinckrodt Institute  
of Radiology  
Washington University  
School of Medicine  
4511 Forest Park Boulevard  
St. Louis, Missouri 63108

**Elliot W. Strong, M.D.**  
Department of Surgery,  
Head and Neck Service  
Memorial Sloan-Kettering  
Cancer Center  
Cornell University Medical  
College  
1275 York Avenue  
New York, New York 10021

**Leonard Weiss,  
Sc.D., M.D., Ph.D.**  
Department of Experimental  
Pathology  
Roswell Park Memorial Institute  
Buffalo, New York 14263

**John Werner, M.D.**  
Department of Radiology  
City of Hope National  
Medical Center  
Duarte, California 91010

**Morris J. Wizenberg, M.D.**  
Department of Radiation Therapy  
University of Oklahoma Hospital  
P.O. Box 25606  
Oklahoma City, Oklahoma 73106

# Preface

This book contains expanded versions of papers presented at a small workshop on metastasis within the lymphatic system, held on May 31 and June 1, 1979, at the University of California at Los Angeles Faculty Center.

This is our third attempt to provide in-depth coverage of metastasis in specified sites in terms of basic sciences, diagnosis, and treatment. In contrast to the previous volumes in this series, that dealt with metastases in the lungs and brain, the present title covers both a complex delivery system and the target organs—the lymph nodes. This dual purpose has necessitated a different format from the previous volumes.

Once again, we are deeply indebted to our contributors for their efforts to provide exhaustive documentation of the various aspects of this central topic in oncology.

*Leonard Weiss  
Harvey A. Gilbert*

# Acknowledgments

The workshop on lymphatic system metastasis, on which this book is based, was sponsored by

Adria Laboratories, Incorporated

Atomic Energy of Canada, Limited

Bristol Laboratories

City of Hope National Medical Center (Gynecologic Oncology Service)

Old Delft Corporation of America

Siemens Corporation

UCLA Jonsson Comprehensive Cancer Center

Varian Corporation

We are grateful to all of these organizations for their support and additionally, to the UCLA Jonsson Comprehensive Cancer Center for acting as hosts for the workshop.

*Leonard Weiss*

*Harvey A. Gilbert*

*Samuel C. Ballon*

## **Chapter 2**

The illustrations are the work of the photography section of the Department of Pathology, University of Saskatchewan. The work described was supported by a grant from the National Cancer Institute of Canada. We are grateful to Mrs. B. Dreher for technologic help, and to Drs. F. McGinty, C. van de Velde, and C. R. Franks for many discussions at varying stages of this work.

## **Chapter 4**

Much of the research described here was sponsored by the National Cancer Institute under contract NO1-CO-75380, with Litton Bionetics, Inc.

## **Chapter 5**

This work was supported in part by grant CAO-5838, from the National Cancer Institute of the National Institutes of Health.

## **Chapter 7**

A portion of the research in this area was supported by the National Cancer Institute of Canada. Appreciation is expressed to Drs. J. Adolph, J. Chorney, and H. Emson for histopathologic material.

## **Chapter 13**

These studies of tumor behavior in carcinoma of the lung have been supported by N.I.H. National Cancer Institute contracts NO1-CM-77153, and NO1-CM-77149.

## **Chapter 15**

The authors acknowledge the significant contribution of Ms. Ann Murphy, Assistant Epidemiologist, in the preparation of the data base, and the statistics for this study. Acknowledgment is also given to Ms. Laura Leonard for coding assistance, and to Ms. Dianne Jolly for obtaining complete follow-up.

## **Chapter 20**

This investigation was supported in part by grants CA 5654 and CA 06294 from the National Cancer Institute, Department of Health, Education, and Welfare.

## **Chapter 27**

Our work described in this chapter was supported by grant CA 3713 from the National Cancer Institute of the National Institutes of Health.

## **Chapter 28**

These investigations were supported by grants CA 12582 and CB 64076TQ from the National Cancer Institute, Department of Health, Education, and Welfare, and the Medical Research Service of the Veterans Administration.

# Introduction

The spread of cancer within the lymphatic system has long been recognized, and the extent of this spread has traditionally been used as the basis for both staging the disease and treating it. Other things being equal, patients with lymph-node metastases do worse than patients without them. The presence or absence of nodal involvement is usually related to the size of the primary cancer: tumors with 2 cm diameters tend to have nodal involvement in 10 to 20% of cases. The incidence increases with the size of the primary lesion. In many types of cancer, lymph-node metastases appear to develop in a more or less orderly anatomic progression from their primary sites. This progress led to the classical approach to radical cancer surgery, the efficacy of which is currently the subject of agonizing review. Except in early disease, metastases are not confined to the lymphatic system and the cancer cannot therefore be eradicated by removal of the primary lesion and its nodal metastases. This does not imply that there is never therapeutic gain from radical procedures, however, since even short-term relief (e.g., 5 years) may be very worthwhile for the patient. Nonetheless, from a mechanistic viewpoint these gains should not be confused with total eradication of disease, manifested as long-term cures without development of distant metastases. The limited success of local therapy *in all but early cancer* has led to the concept of lymph nodes as somewhat passive meters of the extent of cancer, rather than as active limiters of the disease (with the possible exception of early disease), or as exclusive agents in promoting its spread.

This book begins with a section on some of the more general pathobiologic aspects of metastasis in the lymphatic system. The feasibility of certain universal mechanisms and the limitation in interpretation of experimental and clinical data, are discussed in terms of communications between the lymphatic and venous systems, the ultrastructure of lymph nodes in relation to malignant cells lodged in them, and the question of immune response. The controversial topic of tumor immunology is covered briefly, because it is now well appreciated that studies of often highly immunogenic animal tumors have questionable relevance to the total metastatic situation in humans, whose tumors do not appear to be highly immunogenic. In addition, there is reason to suspect that by the time patients are seen by the clinician, any immunologic battles have been lost. This does not exclude a role for immune phenomena in human cancer, however, particularly in subclinical situations.

The second section is concerned with a survey of diagnostic procedures used to assess lymphatic involvement in metastasis. It is not our intention to describe the techniques themselves here but rather to indicate some of their avoidable and unavoidable limitations. For example, the procedure for obtaining specimens is often not considered

by those reviewing data and may generate false results. The method of examining lymph nodes must also be considered because some clearing procedures and multiple sections will reveal cancers in nodes graded as negative by standard techniques. Somewhat surprisingly, these nodal micrometastases are regarded as having little clinical importance. However, removal of involved nodes as part of a staging procedure may modify the subsequent course of disease. In addition to variations in pathologic specimens, account must also be taken of variations in specimens of pathologists. For example, not only has the prognostic significance of sinus histiocytosis in breast cancer evoked a great deal of controversy among surgeons, the existence of sinus histiocytosis as a distinct pathologic entity is not recognized by many pathologists. Detection of involved lymph nodes by radiologic techniques such as lymphangiography, computer-aided tomography, and ultrasound is also not completely reliable. While these procedures have obvious merit, their limitations with respect to false negative results must be borne in mind.

As with most other aspects of metastasis, generalizations about involvement of the lymphatic system have limited value, and it is mandatory to consider the metastasis of specific cancers from specific anatomic sites. Therefore, after some general considerations of node irradiation, chemotherapy, and combined therapy in the third section, the fourth and final section of this book is concerned with detailed considerations of metastasis from specific primary tumors. In some cancers, nodal involvement must almost always be present before spread to distant sites. Limited involvement of lymph nodes by these cancers may be associated with a high likelihood of cure if local treatment of the primary lesion and involved nodes is adequate (for example, primaries in the cervix, head and neck, or vulva). The participants at the meeting agreed that even when dealing with the more curable cancers with lymph node involvement, as soon as the bulk or number of involved nodes exceeds a certain volume, local surgery probably becomes little more than a giant biopsy, possibly affording relief from local symptoms, and removal of potential generalizing sites for additional metastases. Even when irradiation is applied in addition to surgery, the regional disease may be removed, but little survival improvement is obtained. For example, in treating head and neck cancer, increased local control has not similarly improved survival, because the incidence of fatal distant metastases has increased. In other groups of cancers (melanoma, squamous cell carcinoma of the lung, colon cancer), recent information indicates that adequate treatment of nodal involvement limited to one or two very proximal, subclinically involved nodes, is associated with cure. In some cancers responsive to chemotherapy, there appears to be only minimal lowering of the cure rate when limited, or even modest, nodal disease is present (Wilms' tumor and testicular cancer). Finally, there are those cancers in which nodal involvement indicates no lowering of the survival rate (such as well-differentiated thyroid cancer in younger patients). In most cancers, however, even modest nodal involvement indicates visceral metastases.

Efforts were made at the meeting to construct a composite chart, comparing the cure rates for each primary site of cancer as related to the degree of nodal involvement (assessed by number and anatomic site). It soon became obvious that the nuances of each primary site, in terms of histology and the detailed anatomy of the regional lymphatic system, precluded any but the most rudimentary schemes, and would lack clinical relevance. Readers are therefore referred to individual chapters, where the nuances and specifics are presented in detail.

Metastases in the lymphatic system, like so-called solid cancers in other systems and organs, cannot usually be treated effectively in the disseminated stage, and new departures in research of chemotherapy and other forms of systemic therapy are urgently required.

*Leonard Weiss  
Harvey A. Gilbert  
Samuel C. Ballon*

# Contents

**Contributors**

**Preface**

**Acknowledgments**

**Introduction**

## **PART 1**

### **BASIC ASPECTS OF METASTASIS WITHIN THE LYMPHATIC SYSTEM**

<b>Chapter 1</b>	The Pathophysiology of Metastasis within the Lymphatic System Leonard Weiss	<b>2</b>
<b>Chapter 2</b>	Experimental Lymphatic Invasion and Metastasis Ian Carr and Jean Carr	<b>41</b>
<b>Chapter 3</b>	A Note on the Lymph Node as an Immunologic Barrier Malcolm S. Mitchell	<b>74</b>
<b>Chapter 4</b>	Lymph Node and Visceral Metastasis of Cloned Murine Fibrosarcoma Cell Lines Isaiah J. Fidler and Herbert C. Hoover, Jr.	<b>80</b>

## **PART 2**

### **GENERAL CONSIDERATIONS OF DIAGNOSIS**

<b>Chapter 5</b>	Radiologic Imaging Techniques for Diagnosis of Lymph Node Metastases from Solid Tumors Ronald A. Castellino	<b>92</b>
<b>Chapter 6</b>	The Surgeon's Approach to Lymph Node Biopsy and Dissection Yeu-Tsu N. Margaret Lee	<b>119</b>



<b>Chapter 7</b>	The Pathologist's Role in Interpreting Metastatic Lymph Node Disease Ian Carr	<b>138</b>
------------------	---	------------

### **PART 3**

#### **GENERAL THERAPEUTIC CONSIDERATIONS**

<b>Chapter 8</b>	Radiotherapy of Lymph Nodes Containing Metastatic Tumors Morris J. Wizenberg	<b>156</b>
<b>Chapter 9</b>	Effects of Irradiation on Lymph Nodes Carlos A. Perez and Carleton C. Stewart	<b>170</b>
<b>Chapter 10</b>	The Relationship Between Irradiation and Immunologic Responses in Lymph Nodes Dorothy Graves	<b>196</b>
<b>Chapter 11</b>	Chemotherapy of Lymph Node Metastases: Differential Response David Plotkin	<b>200</b>
<b>Chapter 12</b>	The Rationale of Combined Radiotherapy and Chemotherapy in the Management of Cancer Paul Y. M. Chan and John E. Byfield	<b>210</b>

### **PART 4**

#### **METASTASIS WITHIN THE LYMPHATIC SYSTEM FROM DIFFERENT PRIMARY SITES**

<b>Chapter 13</b>	The Meaning of Lymph Node Metastases and Their Treatment: Non-Small Cell Carcinoma of the Lung Clifton F. Mountain and Kay E. Hermes	<b>230</b>
<b>Chapter 14</b>	The Prognostic Significance of Lymph Node Metastases: Carcinoma of the Breast William Brand	<b>239</b>
<b>Chapter 15</b>	The Meaning of Lymph Node Metastases and Their Treatment: Squamous Cell Carcinoma of the Esophagus Clifton F. Mountain and Kay E. Hermes	<b>250</b>